Perioperative tyrosine kinase inhibitors for GIST: standard ... or an idea that needs further investigation?
作者信息
von Mehren Margaret, Watson James C
机构信息
Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA.
出版信息
Oncology (Williston Park). 2009 Jan;23(1):65-6.
Abstract
摘要
相似文献
1
Perioperative tyrosine kinase inhibitors for GIST: standard ... or an idea that needs further investigation?
Oncology (Williston Park). 2009 Jan;23(1):65-6.
2
Recent advances in therapy for gastrointestinal stromal tumors.
Curr Oncol Rep. 2007 May;9(3):165-9. doi: 10.1007/s11912-007-0017-0.
3
Perioperative treatment of gastrointestinal stromal tumors.
Oncology (Williston Park). 2009 Jan;23(1):54-61.
4
Current management of GISTs.
Clin Adv Hematol Oncol. 2010 May;8(5):334.
5
Sunitinib for imatinib-resistant GIST.
Lancet. 2006 Oct 14;368(9544):1303-4. doi: 10.1016/S0140-6736(06)69489-0.
6
Controversies in the surgical management of GIST in the era of imatinib.
Oncology (Williston Park). 2009 Jan;23(1):69, 74-6.
7
Evaluation of regorafenib in colorectal cancer and GIST.
Lancet. 2013 Jan 26;381(9863):273-5. doi: 10.1016/S0140-6736(12)62006-6. Epub 2012 Nov 22.
8
[Evidence-based treatment of gastrointestinal stromal tumor (GIST) with tyrosine kinase inhibitors-imatinib and sunitinib].
Gan To Kagaku Ryoho. 2011 May;38(5):733-7.
9
Clinical efficacy of second-generation tyrosine kinase inhibitors in imatinib-resistant gastrointestinal stromal tumors: a meta-analysis of recent clinical trials.
Drug Des Devel Ther. 2014 Oct 30;8:2061-7. doi: 10.2147/DDDT.S63840. eCollection 2014.
10
Hits and misses in targeting pediatric cancers.
Pediatr Blood Cancer. 2009 Jul;52(7):751-2. doi: 10.1002/pbc.21937.
引用本文的文献
1
Get the GIST? An overview of gastrointestinal stromal tumours.
Ir J Med Sci. 2016 May;185(2):319-26. doi: 10.1007/s11845-016-1410-1. Epub 2016 Feb 1.
2
Prolonged Therapy with Imatinib Mesylate before Surgery for Advanced Gastrointestinal Stromal Tumor Results of a Phase II Trial.
Int J Surg Oncol. 2012;2012:761576. doi: 10.1155/2012/761576. Epub 2012 Dec 17.
3
(18)FDG-PET at 1-Month Intervals Is a Better Predictive Marker for GISTs That Are Difficult to Be Diagnosed Histopathologically: A Case Report.
Case Rep Oncol Med. 2011;2011:638794. doi: 10.1155/2011/638794. Epub 2011 Oct 11.
本文引用的文献
1
Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): early results of RTOG 0132/ACRIN 6665.
J Surg Oncol. 2009 Jan 1;99(1):42-7. doi: 10.1002/jso.21160.
2
Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033.
J Clin Oncol. 2008 Feb 1;26(4):626-32. doi: 10.1200/JCO.2007.13.4452.
3
Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria.
J Clin Oncol. 2007 May 1;25(13):1753-9. doi: 10.1200/JCO.2006.07.3049.
4
Surgery of residual disease following molecular-targeted therapy with imatinib mesylate in advanced/metastatic GIST.
Ann Surg. 2007 Mar;245(3):341-6. doi: 10.1097/01.sla.0000242710.36384.1b.
5
Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial.
Lancet. 2006 Oct 14;368(9544):1329-38. doi: 10.1016/S0140-6736(06)69446-4.
6
Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors.
J Clin Oncol. 2006 May 20;24(15):2325-31. doi: 10.1200/JCO.2005.05.3439.
7
KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours.
Eur J Cancer. 2006 May;42(8):1093-103. doi: 10.1016/j.ejca.2006.01.030. Epub 2006 Apr 18.
8
Surgical treatment of patients with initially inoperable and/or metastatic gastrointestinal stromal tumors (GIST) during therapy with imatinib mesylate.
J Surg Oncol. 2006 Mar 15;93(4):304-11. doi: 10.1002/jso.20466.
9
Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial.
Lancet. 2004;364(9440):1127-34. doi: 10.1016/S0140-6736(04)17098-0.
Zotero 插件